{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:23:53Z","timestamp":1791491033786,"version":"4.3.4"},"reference-count":52,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute On Drug Abuse (NIDA) of the National Institutes of Health (NIH)","award":["R01DA032080"],"award-info":[{"award-number":["R01DA032080"]}]},{"name":"National Institute On Drug Abuse (NIDA) of the National Institutes of Health (NIH)","award":["U2C DA 050097"],"award-info":[{"award-number":["U2C DA 050097"]}]},{"name":"National Institute On Drug Abuse (NIDA) of the National Institutes of Health (NIH)","award":["DP2 DA053730"],"award-info":[{"award-number":["DP2 DA053730"]}]},{"name":"National Institute On Drug Abuse (NIDA) of the National Institutes of Health (NIH)","award":["R00 DA043011"],"award-info":[{"award-number":["R00 DA043011"]}]},{"name":"National Institute On Drug Abuse (NIDA) of the National Institutes of Health (NIH)","award":["R61 DA060627"],"award-info":[{"award-number":["R61 DA060627"]}]},{"name":"National Institute On Drug Abuse (NIDA) of the National Institutes of Health (NIH)","award":["R01MD016744"],"award-info":[{"award-number":["R01MD016744"]}]},{"name":"Albert Einstein Global Health Center","award":["R01DA032080"],"award-info":[{"award-number":["R01DA032080"]}]},{"name":"Albert Einstein Global Health Center","award":["U2C DA 050097"],"award-info":[{"award-number":["U2C DA 050097"]}]},{"name":"Albert Einstein Global Health Center","award":["DP2 DA053730"],"award-info":[{"award-number":["DP2 DA053730"]}]},{"name":"Albert Einstein Global Health Center","award":["R00 DA043011"],"award-info":[{"award-number":["R00 DA043011"]}]},{"name":"Albert Einstein Global Health Center","award":["R61 DA060627"],"award-info":[{"award-number":["R61 DA060627"]}]},{"name":"Albert Einstein Global Health Center","award":["R01MD016744"],"award-info":[{"award-number":["R01MD016744"]}]},{"name":"JCOIN cooperative","award":["R01DA032080"],"award-info":[{"award-number":["R01DA032080"]}]},{"name":"JCOIN cooperative","award":["U2C DA 050097"],"award-info":[{"award-number":["U2C DA 050097"]}]},{"name":"JCOIN cooperative","award":["DP2 DA053730"],"award-info":[{"award-number":["DP2 DA053730"]}]},{"name":"JCOIN cooperative","award":["R00 DA043011"],"award-info":[{"award-number":["R00 DA043011"]}]},{"name":"JCOIN cooperative","award":["R61 DA060627"],"award-info":[{"award-number":["R61 DA060627"]}]},{"name":"JCOIN cooperative","award":["R01MD016744"],"award-info":[{"award-number":["R01MD016744"]}]},{"name":"NIDA","award":["R01DA032080"],"award-info":[{"award-number":["R01DA032080"]}]},{"name":"NIDA","award":["U2C DA 050097"],"award-info":[{"award-number":["U2C DA 050097"]}]},{"name":"NIDA","award":["DP2 DA053730"],"award-info":[{"award-number":["DP2 DA053730"]}]},{"name":"NIDA","award":["R00 DA043011"],"award-info":[{"award-number":["R00 DA043011"]}]},{"name":"NIDA","award":["R61 DA060627"],"award-info":[{"award-number":["R61 DA060627"]}]},{"name":"NIDA","award":["R01MD016744"],"award-info":[{"award-number":["R01MD016744"]}]},{"name":"National Institute on Minority Health and Health Disparities (NIMHD)","award":["R01DA032080"],"award-info":[{"award-number":["R01DA032080"]}]},{"name":"National Institute on Minority Health and Health Disparities (NIMHD)","award":["U2C DA 050097"],"award-info":[{"award-number":["U2C DA 050097"]}]},{"name":"National Institute on Minority Health and Health Disparities (NIMHD)","award":["DP2 DA053730"],"award-info":[{"award-number":["DP2 DA053730"]}]},{"name":"National Institute on Minority Health and Health Disparities (NIMHD)","award":["R00 DA043011"],"award-info":[{"award-number":["R00 DA043011"]}]},{"name":"National Institute on Minority Health and Health Disparities (NIMHD)","award":["R61 DA060627"],"award-info":[{"award-number":["R61 DA060627"]}]},{"name":"National Institute on Minority Health and Health Disparities (NIMHD)","award":["R01MD016744"],"award-info":[{"award-number":["R01MD016744"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Polysubstance use (PSU), injection drug use (IDU), and equipment sharing are associated with bloodborne infection (BBI) transmission risk, particularly Hepatitis C Virus (HCV), yet data on PSU in low- and middle-income countries (LMICs) is limited. We report on baseline PSU, medication-assisted treatment (MAT) engagement, and motivation to reduce IDU among 95 people who inject drugs (PWID) who accessed needle and syringe programs (NSP) in Nairobi and Coastal Kenya prior to HCV treatment. Bivariate and multivariate logistic regression were used to examine the associations between PSU and behaviors that confer HCV transmission and acquisition risks. Most participants (70.5%) reported PSU in the last 30 days, and one-third (35.8%) reported PSU exclusive to just heroin and cannabis use. Common combinations were heroin and cannabis (49.3%), and heroin, cannabis, and bugizi (flunitrazepam) (29.9%). Participants at baseline were receiving MAT (69.5%), already stopped or reduced IDU (30.5%), and were HIV-positive (40%). PSU was significantly associated with IDU (p = 0.008) and the number of times (p = 0.016) and days (p = 0.007) injected in the last 30 days. Participants reported high PSU and equipment sharing, despite high MAT engagement. While co-locating BBI treatment within existing harm reduction services is necessary to promote uptake and curb re-infection, tailored services may be needed to address PSU, particularly in LMICs.<\/jats:p>","DOI":"10.3390\/v16081277","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T05:19:38Z","timestamp":1723439978000},"page":"1277","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Polysubstance Use and Related Risk Behaviors among People Who Inject Drugs in Kenya Preparing for Hepatitis C Virus Treatment"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8805-270X","authenticated-orcid":false,"given":"Lindsey R.","family":"Riback","sequence":"first","affiliation":[{"name":"Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy","family":"Nyakowa","sequence":"additional","affiliation":[{"name":"Kenya Ministry of Health, National AIDS&STI Control Program (NASCOP), 19361 Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lizcano","sequence":"additional","affiliation":[{"name":"Yale School of Nursing, Yale University, Orange, CT 06477, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenshu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Cherutich","sequence":"additional","affiliation":[{"name":"Kenya Ministry of Health, National AIDS&STI Control Program (NASCOP), 19361 Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Kurth","sequence":"additional","affiliation":[{"name":"New York Academy of Medicine, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global Prevalence of Injecting Drug Use and Sociodemographic Characteristics and Prevalence of Hiv, Hbv, and Hcv in People Who Inject Drugs: A Multistage Systematic Review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_2","unstructured":"WHO (2024, March 13). People Who Inject Drugs. World Health Organization. Available online: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/populations\/people-who-inject-drugs#:~:text=Injecting%20drug%20use%20accounts%20for,attributable%20to%20injecting%20drug%20use."},{"key":"ref_3","unstructured":"World Health Organization (2017). Global Hepatitis Report, World Health Organization."},{"key":"ref_4","unstructured":"Weinbaum, C., Lyerla, R., Margolis, H.S., and Centers for Disease Control and Prevention (2003). Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings. Centers for Disease Control and Prevention. MMWR Recomm. Rep., 52."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.drugpo.2011.08.005","article-title":"The Accessibility, Acceptability, Health Impact and Cost Implications of Primary Healthcare Outlets That Target Injecting Drug Users: A Narrative Synthesis of Literature","volume":"23","author":"Islam","year":"2012","journal-title":"Int. J. Drug Policy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S2468-1253(16)30182-0","article-title":"Incidence, Risk Factors, and Prevention of Hepatitis C Reinfection: A Population-Based Cohort Study","volume":"2","author":"Islam","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Muller, A., Vlahov, D., Akiyama, M.J., and Kurth, A. (2020). Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17144951"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/cid\/cix126","article-title":"Risk Factors for Hepatitis C Virus Reinfection after Sustained Virologic Response in Patients Coinfected with Hiv","volume":"64","author":"Young","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","unstructured":"National Harm Reduction Coalition (2020). Getting off Right: A Safety Manual for Injection Drug Users, National Harm Reduction Coalition."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3399\/bjgp16X685333","article-title":"The Physical Health of People Who Inject Drugs: Complexities, Challenges, and Continuity","volume":"66","author":"Cornford","year":"2016","journal-title":"Br. J. Gen. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3399\/bjgp16X683365","article-title":"Managing Physical Health Problems in People Who Inject Drugs","volume":"66","author":"Lawson","year":"2016","journal-title":"Br. J. Gen. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S2468-1253(17)30249-2","article-title":"Hepatitis C in Sub-Saharan Africa: The Current Status and Recommendations for Achieving Elimination by 2030","volume":"2","author":"Sonderup","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(18)30413-8","article-title":"Direct-Acting Antiviral Therapy in Sub-Saharan Africa","volume":"4","author":"Spearman","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global Prevalence and Genotype Distribution of Hepatitis C Virus Infection in 2015: A Modelling Study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"103959","DOI":"10.1016\/j.drugpo.2023.103959","article-title":"Predictors of Hepatitis C Cure among People Who Inject Drugs Treated with Directly Observed Therapy Supported by Peer Case Managers in Kenya","volume":"113","author":"Akiyama","year":"2023","journal-title":"Int. J. Drug Policy"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Fadnes, L.T., Aas, C.F., Vold, J.H., Leiva, R.A., Ohldieck, C., Chalabianloo, F., Skurtveit, S., Lygren, O.J., Dalgard, O., and Vickerman, P. (2021). Integrated Treatment of Hepatitis C Virus Infection among People Who Inject Drugs: A Multicenter Randomized Controlled Trial (Intro-Hcv). PLoS Med., 18.","DOI":"10.1371\/journal.pmed.1003653"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/ADM.0000000000000807","article-title":"Initiation of Low-Threshold Buprenorphine in Nontreatment Seeking Patients with Opioid Use Disorder Engaged in Hepatitis C Treatment","volume":"16","author":"Hill","year":"2022","journal-title":"J. Addict. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.drugpo.2019.09.002","article-title":"Hepatitis C Virus Treatment in People Who Inject Drugs (Pwid) in Bangladesh","volume":"74","author":"Rahman","year":"2019","journal-title":"Int. J. Drug Policy"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S2468-1253(22)00275-8","article-title":"Patient-Centred Models of Hepatitis C Treatment for People Who Inject Drugs: A Multicentre, Pragmatic Randomised Trial","volume":"7","author":"Litwin","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_20","unstructured":"(2016). Behavioural and Serological Surveillance Amongst Key Populations at Risk of Hiv in Selected Areas of Bangladesh, 2016."},{"key":"ref_21","unstructured":"(2016). Mapping Study and Size Estimations of Key Populations in Bangladesh for Hiv Programs 2015\u20132016."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1477-7517-7-2","article-title":"Giving Away Used Injection Equipment: Missed Prevention Message?","volume":"7","author":"Strike","year":"2010","journal-title":"Harm Reduct. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/09540129308258596","article-title":"Severity of Heroin Dependence and Hiv Risk. Ii. Sharing Injecting Equipment","volume":"5","author":"Gossop","year":"1993","journal-title":"AIDS Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.1991.10472569","article-title":"Drug Sharing and Hiv Transmission Risks: The Practice of Frontloading in the Dutch Injecting Drug User Population","volume":"23","author":"Grund","year":"1991","journal-title":"J. Psychoactive Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00002030-199603000-00010","article-title":"Frontloading: A Risk Factor for Hiv and Hepatitis C Virus Infection among Injecting Drug Users in Berlin","volume":"10","author":"Stark","year":"1996","journal-title":"AIDS"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/YCO.0000000000000069","article-title":"Polysubstance Use: Diagnostic Challenges, Patterns of Use and Health","volume":"27","author":"Connor","year":"2014","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"799","DOI":"10.15288\/jsad.2018.79.799","article-title":"Polysubstance Use by Stimulant Users: Health Outcomes over Three Years","volume":"79","author":"Timko","year":"2018","journal-title":"J. Stud. Alcohol. Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1360-0443.2003.00236.x","article-title":"Understanding Polydrug Use: Review of Heroin and Cocaine Co-Use","volume":"98","author":"Leri","year":"2003","journal-title":"Addiction"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"108527","DOI":"10.1016\/j.drugalcdep.2021.108527","article-title":"Hepatitis C Virus Infection and Polysubstance Use among Young Adult People Who Inject Drugs in a Rural County of New Mexico","volume":"220","author":"Wagner","year":"2021","journal-title":"Drug Alcohol. Depend."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"740","DOI":"10.15288\/jsad.2020.81.740","article-title":"The Relationship between Polysubstance Injection Drug Use, Hiv Risk Behaviors, and Interest in Pre-Exposure Prophylaxis (Prep) among People Who Inject Drugs in Rural West Virginia","volume":"81","author":"Schneider","year":"2020","journal-title":"J. Stud. Alcohol. Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.drugalcdep.2011.03.018","article-title":"Use of Item Response Theory and Latent Class Analysis to Link Poly-Substance Use Disorders with Addiction Severity, Hiv Risk, and Quality of Life among Opioid-Dependent Patients in the Clinical Trials Network","volume":"118","author":"Wu","year":"2011","journal-title":"Drug Alcohol. Depend."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1477-7517-11-17","article-title":"\u2018South Asian Cocktail\u2019\u2014The Concurrent Use of Opioids, Benzodiazepines and Antihistamines among Injecting Drug Users in Nepal and Associations with Hiv Risk Behaviour","volume":"11","author":"Ojha","year":"2014","journal-title":"Harm Reduct. J."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cai, Y., Dai, Z., Wen, S., and Bhandari, R. (2020). Risk Factors Associated with Infection of Blood-Borne Virus among People Who Used Methamphetamine. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-05464-y"},{"key":"ref_34","unstructured":"National AIDS & STI Control Program (2016). Guidelines on Use of Antiretroviral Drugs for Treating and Preventing Hiv Infections in Kenya."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12954-021-00580-7","article-title":"Barriers and Facilitators of Hiv and Hepatitis C Care among People Who Inject Drugs in Nairobi, Kenya: A Qualitative Study with Peer Educators","volume":"18","author":"Guthrie","year":"2021","journal-title":"Harm Reduct. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/QAD.0000000000003382","article-title":"Modelling the Impact of Hiv and Hcv Prevention and Treatment Interventions among People Who Inject Drugs in Kenya","volume":"36","author":"Stone","year":"2022","journal-title":"AIDS"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1080\/17441692.2022.2110919","article-title":"Challenges and Best Practices for Hepatitis C Care among People Who Inject Drugs in Resource Limited Settings: Focus Group Discussions with Healthcare Providers in Kenya","volume":"17","author":"Seu","year":"2022","journal-title":"Glob. Public. Health"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/QAI.0000000000000769","article-title":"Hiv Prevalence, Estimated Incidence, and Risk Behaviors among People Who Inject Drugs in Kenya","volume":"70","author":"Kurth","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S1473-3099(19)30264-6","article-title":"Prevalence, Estimated Incidence, Risk Behaviours, and Genotypic Distribution of Hepatitis C Virus among People Who Inject Drugs Accessing Harm-Reduction Services in Kenya: A Retrospective Cohort Study","volume":"19","author":"Akiyama","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/jvh.13662","article-title":"Hepatitis C Treatment Outcomes among People Who Inject Drugs Accessing Harm Reduction Settings in Kenya","volume":"29","author":"Akiyama","year":"2022","journal-title":"J. Viral Hepat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1007\/s10461-014-0936-3","article-title":"Hiv and Sti Prevalence and Injection Behaviors among People Who Inject Drugs in Nairobi: Results from a 2011 Bio-Behavioral Study Using Respondent-Driven Sampling","volume":"19","author":"Tun","year":"2015","journal-title":"AIDS Behav."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lalwani, K., Whitehorne-Smith, P., Walcott, G., McLeary, J.G., Mitchell, G., and Abel, W. (2022). Prevalence and Sociodemographic Factors Associated with Polysubstance Use: Analysis of a Population-Based Survey in Jamaica. BMC Psychiatry, 22.","DOI":"10.1186\/s12888-022-04160-2"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/QAI.0000000000003356","article-title":"Polysubstance Use Profiles and Hiv Viremia in a South African Cohort of Female Sex Workers: A Latent Class Analysis","volume":"95","author":"Rosen","year":"2024","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7517-2-12","article-title":"The Rise of Injecting Drug Use in East Africa: A Case Study from Kenya","volume":"2","author":"Beckerleg","year":"2005","journal-title":"Harm Reduct. J."},{"key":"ref_45","unstructured":"Girma, E., Mulatu, T., and Ketema, B. (2020). Polysubstance Use Behavior among the Male Population in Ethiopia: Findings from the 2016 Ethiopia Demographic and Health Survey. Ethiop. J. Health Dev., 34."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1080\/08897077.2021.2007520","article-title":"Characteristics Associated with Motivation to Stop Substance Use and Improve Skin and Needle Hygiene among Hospitalized Patients Who Inject Drugs","volume":"43","author":"Kimmel","year":"2022","journal-title":"Subst. Abus."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/jrh.12388","article-title":"Motivation to Change and Treatment Participation among Syringe Service Program Utilizers in Rural Kentucky","volume":"36","author":"Surratt","year":"2020","journal-title":"J. Rural Health"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1360-0443.2000.95341912.x","article-title":"Consistency of Self-Administered and Interview-Based Addiction Severity Index Composite Scores","volume":"95","author":"Rosen","year":"2000","journal-title":"Addiction"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"594","DOI":"10.7326\/M18-1715","article-title":"Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial","volume":"170","author":"Akiyama","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and Velpatasvir for Hepatitis C Virus Infection in People with Recent Injection Drug Use (Simplify): An Open-Label, Single-Arm, Phase 4, Multicentre Trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","article-title":"Direct-Acting Antiviral Treatment for Hepatitis C among People Who Use or Inject Drugs: A Systematic Review and Meta-Analysis","volume":"3","author":"Hajarizadeh","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"ofy048","DOI":"10.1093\/ofid\/ofy048","article-title":"Hepatitis C Treatment Outcomes for People Who Inject Drugs Treated in an Accessible Care Program Located at a Syringe Service Program","volume":"5","author":"Eckhardt","year":"2018","journal-title":"Open Forum Infect. Dis."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/8\/1277\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:34:27Z","timestamp":1760110467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/8\/1277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":52,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["v16081277"],"URL":"https:\/\/doi.org\/10.3390\/v16081277","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,10]]}}}